Trial was evaluating the drug in patients with embolic stroke of undetermined source (ESUS). - News - PharmaTimes|Trial was evaluating the drug in patients with embolic stroke of undetermined source (ESUS).|Trial was evaluating the drug in patients with embolic stroke of undetermined source (ESUS).
by George Underwood
www.pharmatimes.com/news/bayer_halts_xarelto_trial_1207036Shire is reportedly in advanced talks to acquire Baxter's biopharma spin-off Baxalta and may announce a deal this week. - News - PharmaTimes|Shire is reportedly in advanced talks to acquire Baxter's biopharma spin-off Baxalta and may announce a deal this week.|Shire is reportedly in advanced talks to acquire Baxter's biopharma spin-off Baxalta and may announce a deal this week.
by George Underwood
www.pharmatimes.com/news/shire_and_baxalta_near_deal_1020698CRO hopes partnership will accelerate drugs' time to market - News - PharmaTimes|CRO hopes partnership will accelerate drugs' time to market|CRO hopes partnership will accelerate drugs' time to market
by George Underwood
www.pharmatimes.com/news/medidata_teams_with_pharm-olam_1256852Appointment boosts healthcare offering - Appointments - PharmaTimes|Appointment boosts healthcare offering|Appointment boosts healthcare offering
by George Underwood
www.pharmatimes.com/appointments/lansons_recruits_kate_aldous_1029021Vaccine uses T-cells to potentially attack multiple strains of the virus - News - PharmaTimes|Vaccine uses T-cells to potentially attack multiple strains of the virus|Vaccine uses T-cells to potentially attack multiple strains of the virus
by George Underwood
www.pharmatimes.com/news/universal_flu_vaccine_to_be_tested_1206771If approved by the FDA, this would mark the third indication for Keytruda in metastatic NSCLC in the United States based on OS data - News - PharmaTimes|If approved by the FDA, this would mark the third indication for Keytruda in metastatic NSCLC in the United States based on OS data|If approved by the FDA, this would mark the third indication for Keytruda in metastatic NSCLC in the United States based on OS data
by George Underwood
www.pharmatimes.com/news/fda_grants_keytruda_priority_review_1233852Drug is only darunavir-based STR indicated for HIV-1 infection in adults and adolescents - News - PharmaTimes|Drug is only darunavir-based STR indicated for HIV-1 infection in adults and adolescents|Drug is only darunavir-based STR indicated for HIV-1 infection in adults and adolescents
by George Underwood
www.pharmatimes.com/news/ec_approves_janssens_symtuza_1206421London-based agency begins trading today - News - PharmaTimes|London-based agency begins trading today|London-based agency begins trading today
by George Underwood
www.pharmatimes.com/news/method_medical_media_launches_1204334Rejection is another win for drugs' originator Roche - News - PharmaTimes|Rejection is another win for drugs' originator Roche|Rejection is another win for drugs' originator Roche
by George Underwood
www.pharmatimes.com/news/novartis_biosimilar_rituximab_delayed_in_us_1234248Tafinlar/Mekinist combo is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation - News - PharmaTimes|Tafinlar/Mekinist combo is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation|Tafinlar/Mekinist combo is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation
by George Underwood
www.pharmatimes.com/news/fda_approval_for_novartis_melanoma_combo_1233840
